Benitec Biopharma (BNTC) Competitors $14.00 +0.09 (+0.65%) Closing price 04:00 PM EasternExtended Trading$13.96 -0.04 (-0.29%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTC vs. SPRY, PAHC, ABCL, EVO, TLRY, XERS, PGEN, ELVN, COLL, and CVACShould you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include ARS Pharmaceuticals (SPRY), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Evotec (EVO), Tilray Brands (TLRY), Xeris Biopharma (XERS), Precigen (PGEN), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. Benitec Biopharma vs. Its Competitors ARS Pharmaceuticals Phibro Animal Health AbCellera Biologics Evotec Tilray Brands Xeris Biopharma Precigen Enliven Therapeutics Collegium Pharmaceutical CureVac ARS Pharmaceuticals (NASDAQ:SPRY) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk. Does the media favor SPRY or BNTC? In the previous week, ARS Pharmaceuticals had 13 more articles in the media than Benitec Biopharma. MarketBeat recorded 13 mentions for ARS Pharmaceuticals and 0 mentions for Benitec Biopharma. ARS Pharmaceuticals' average media sentiment score of 1.46 beat Benitec Biopharma's score of 1.45 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment ARS Pharmaceuticals Positive Benitec Biopharma Positive Which has more volatility and risk, SPRY or BNTC? ARS Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Do analysts prefer SPRY or BNTC? ARS Pharmaceuticals presently has a consensus target price of $32.50, indicating a potential upside of 204.02%. Benitec Biopharma has a consensus target price of $26.00, indicating a potential upside of 85.71%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has better valuation and earnings, SPRY or BNTC? ARS Pharmaceuticals has higher revenue and earnings than Benitec Biopharma. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M11.85$8M-$0.49-21.82Benitec Biopharma$80K4,593.75-$21.75M-$1.51-9.27 Do institutionals and insiders believe in SPRY or BNTC? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 1.3% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SPRY or BNTC more profitable? Benitec Biopharma has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. ARS Pharmaceuticals' return on equity of -21.85% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-42.74% -21.85% -15.88% Benitec Biopharma N/A -38.26%-35.71% SummaryARS Pharmaceuticals beats Benitec Biopharma on 12 of the 16 factors compared between the two stocks. Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTC vs. The Competition Export to ExcelMetricBenitec BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$365.14M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-9.2720.8978.4326.42Price / Sales4,593.75458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book2.999.9310.916.06Net Income-$21.75M-$53.38M$3.29B$266.28M7 Day Performance7.44%0.05%0.01%-0.76%1 Month Performance20.48%7.08%7.06%3.83%1 Year Performance61.85%11.92%50.09%24.39% Benitec Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTCBenitec Biopharma1.6686 of 5 stars$14.00+0.6%$26.00+85.7%+54.9%$365.14M$80K-9.2720News CoverageGap DownSPRYARS Pharmaceuticals3.0478 of 5 stars$13.51+0.1%$31.00+129.5%-8.9%$1.33B$89.15M-27.5790News CoveragePositive NewsAnalyst ForecastPAHCPhibro Animal Health4.3141 of 5 stars$31.94-1.6%$24.40-23.6%+92.2%$1.32B$1.02B40.951,940ABCLAbCellera Biologics2.3231 of 5 stars$4.23-3.6%$8.00+89.1%+59.6%$1.31B$32.88M-7.69500EVOEvotec2.0452 of 5 stars$3.57-1.9%$5.40+51.3%-0.3%$1.29B$777.33M0.004,827Positive NewsAnalyst ForecastTLRYTilray Brands3.1735 of 5 stars$1.39+20.9%$1.94+39.4%-29.5%$1.27B$821.31M-0.602,842Short Interest ↓XERSXeris Biopharma3.5917 of 5 stars$7.77+0.3%$7.08-8.8%+202.7%$1.25B$203.07M-37.00290Short Interest ↓PGENPrecigen4.2938 of 5 stars$3.98-4.8%$8.25+107.3%+348.1%$1.25B$3.92M-9.48190ELVNEnliven Therapeutics2.9407 of 5 stars$19.94-4.4%$41.20+106.6%-5.6%$1.24BN/A-9.9750COLLCollegium Pharmaceutical2.7149 of 5 stars$38.77-0.9%$42.33+9.2%+5.8%$1.23B$631.45M37.28210Insider TradeCVACCureVac4.5242 of 5 stars$5.40-0.7%$6.83+26.5%+75.2%$1.22B$579.18M5.63880Positive News Related Companies and Tools Related Companies SPRY Alternatives PAHC Alternatives ABCL Alternatives EVO Alternatives TLRY Alternatives XERS Alternatives PGEN Alternatives ELVN Alternatives COLL Alternatives CVAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTC) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BNTC Stock Alerts